Search results
2 days ago · Darzalex (daratumumab) plus Velcade (bortezomib), lenalidomide (Revlimid) and dexamethasone (D-VRd), followed by autologous stem cell transplant (ASCT), D-VRd consolidation (treatment after ASCT) and Darzalex plus Revlimid (DR) maintenance improved rates of sustained minimal residual disease (MRD; measure of remaining cancer cells after treatment) negativity compared with VRd induction, ASCT ...
3 days ago · The intense nature of a transplant means many patients still suffer serious short and long-term adverse effects and reduced quality of life after treatment. 7 On average, 5-year survival post-transplant sits at little over 50%. 8 What's more, disparities in access to and recovery from transplant—due to age, ethnicity, socioeconomic status and ...
4 days ago · Sequencing of Cell Therapies in Multiple Myeloma Continues Evolving. During a Case-Based Roundtable® event, Tara K. Gregory, MD, discussed how to implement use of bispecific T-cell engagers in patients with relapsed/refractory multiple myeloma in the second article of a 2-part series. KEY TAKEAWAYS FROM TARA K. GREGORY, MD.
2 days ago · The suppression of Tregs and recovery of CD8 + T-cells leading to a low Treg/effector cell ratio following an autologous stem cell transplant (ASCT) may make the immune milieu more supportive for ...
1 day ago · AbstractPurpose:. The purpose of this study was to investigate the remodeling of the multiple myeloma microenvironment after B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T (CAR-T) cell therapy.Experimental Design:. We performed single-cell RNA sequencing on paired bone marrow specimens (n = 14) from seven patients with multiple myeloma before (i.e., baseline, “day ...
2 days ago · Multiple myeloma (MM) is a hematological cancer characterized by the abnormal proliferation of plasma cells. Initial treatments often include immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and monoclonal antibodies (mAbs). Despite salient progress in diagnosis and treatment, most MM patients typically have a median life expectancy of only four to five years after starting ...
2 days ago · 1 Introduction. Multiple myeloma (MM) is the second most common hematologic malignancy, which originates from the proliferation of clonal plasma cells [].It was reported that there were 16,500 newly diagnosed patients with MM in China and the age-standardized incidence rate was 1.03/100,000 in 2016 and has an increasing incidence and prevalence in many regions [].
